Canada markets open in 4 hours 36 minutes

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
56.48+0.22 (+0.39%)
At close: 04:00PM EDT
55.92 -0.56 (-0.99%)
After hours: 06:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close56.26
Open56.45
Bid0.00 x 900
Ask57.88 x 1000
Day's Range56.14 - 56.51
52 Week Range31.45 - 68.08
Volume1,568,272
Avg. Volume2,807,831
Market Cap10.208B
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-7.18
Earnings DateMay 17, 2024 - May 21, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.32
  • Reuters

    HIGHLIGHTS-Novo Nordisk hopes to launch experimental obesity drug this decade

    Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade. Research head Lange said the drugmaker could launch the pill version of its experimental weight loss drug amycretin this decade. It expects both new experimental obesity drugs cagrisema and amycretin to lead to greater weight loss than its hugely popular Wegovy.

  • Business Wire

    Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment

    SOMERSET, N.J., March 07, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community. The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives.

  • Zacks

    Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down

    Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.